$9.34
-0.06 (-0.64%)
Seattle Genetics, Inc. (SGEN)
CAPS Rating:
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.